Johnson & Johnson to Feature Analysis from P-II (DAHLIAS) Study of Nipocalimab for Treating Sjögren’s Disease at ACR Convergence 2024
Shots:
- J&J to highlight 43 presentations incl. data from P-II (DAHLIAS) study assessing nipocalimab (5/15mg/kg, IV, Q2W) vs PBO in adults (n=163; 18-75yrs.) with mod. to sev. primary SjD, seropositive for anti-Ro60/52 antibodies, for 22wks. alongside SoC, at ACR 2024
- Study showed improvement in ClinESSDAI scores at 24wks. (greatest in those with high baseline anti-Ro & anti-La Abs), meeting 1 & 2EPs, with disease activity & reduced IgG by over 77% with 15mg/kg
- Patients also experienced improvement in symptoms like mouth dryness, eye dryness, vaginal dryness, fatigue & joint pain, with 32.7% vs 16% patients on 15 mg/kg showing increased salivary flow at wk.24
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related Posts:- Johnson & Johnson Reports Nipocalimab’s BLA Submission to the US FDA for Treating Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
